Pharma Equity Group A/S Stock

Equities

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen 10:24:07 2024-04-19 am EDT After market 10:44:42 am
0.299 DKK -0.33% Intraday chart for Pharma Equity Group A/S 0.289 -3.34%
Sales 2022 - Sales 2023 - Capitalization 440M 3.08B
Net income 2022 -9M -62.96M Net income 2023 -24M -168M EV / Sales 2022 * -
Net cash position 2022 2.25M 15.73M Net Debt 2023 25.99M 182M EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
-18.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 98.63%
More Fundamentals * Assessed data
Dynamic Chart
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051 CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024 CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial CI
Pharma Equity Group A/S Approves Board Appointments CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method MT
More news
1 day-5.33%
1 week-4.62%
Current month-19.72%
1 month-18.82%
3 months-21.47%
6 months-43.33%
Current year-32.79%
More quotes
1 week
0.28
Extreme 0.276
0.33
1 month
0.28
Extreme 0.276
0.38
Current year
0.25
Extreme 0.252
0.44
1 year
0.24
Extreme 0.236
0.60
3 years
0.24
Extreme 0.236
0.90
5 years
0.24
Extreme 0.236
0.90
10 years
0.24
Extreme 0.236
0.90
More quotes
Managers TitleAgeSince
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - 23-05-31
Chief Tech/Sci/R&D Officer 79 -
Members of the board TitleAgeSince
Chairman - 23-02-28
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-19 0.299 -0.33% 1 244 804
24-04-18 0.3 0.00% 95,722
24-04-17 0.3 +2.74% 329,726
24-04-16 0.292 -2.67% 346,880
24-04-15 0.3 -0.99% 182,846

Delayed Quote Nasdaq Copenhagen, April 19, 2024 at 08:37 am EDT

More quotes
Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.
Calendar
More about the company